金城醫藥(300233.SZ):擬購買新型抗生素一類新藥利他唑酮幹混懸劑臨牀試驗批件及相關技術
格隆匯1月23日丨金城醫藥(300233.SZ)公佈,2020年1月21日,公司控股孫公司廣東賽法洛藥業有限公司(“賽法洛藥業”或“乙方”)與四川賽卓藥業股份有限公司(“賽卓藥業”或“甲方”)簽訂了《新藥研發項目轉讓合同》,甲方擬向賽法洛藥業轉讓一類新藥利他唑酮幹混懸劑臨牀試驗批件(批件號為:【2018L02182】)及全套申報資料和其他技術資料,以及相關技術成果。
利他唑酮屬於惡唑烷酮類抗菌藥物,為國家十二五重大科技專項中的新藥創制項目,其原專利權人為中國醫學科學院生物技術研究所。利他唑酮是繼磺胺類和喹諾酮類之後新上市的一種結構全新的化學合成抗菌藥物,其獨特的作用機制和良好的抗菌活性,抗菌譜覆蓋了革蘭陽性球菌,被認為是解決革蘭陽性菌耐藥的新方向和新希望,適用於由金黃色葡萄球菌(甲氧西林敏感或耐藥的菌株)引起的醫院或社區獲得性肺炎,皮膚和皮膚軟組織感染、萬古黴素耐藥的屎腸球菌感染等。
此次技術轉讓完成後,公司在注重基礎頭孢抗生素髮展的同時,開發新型惡唑烷酮類抗生素以助力解決革蘭陽性菌耐藥問題。公司藉助該產品技術進一步提升公司在抗生素終端製劑技術的實力,豐富公司金品抗生素的產品線,為公司在抗感染領域的深度發展奠定基礎。該項目產品上市後,可以為公司業績提供新的增長點,提升公司核心競爭力和可持續發展能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.